Full Press Release Details
Therapeutics Announces Third Quarter 2021 Financial Results
Expect to receive confirmatory guidance on Renazorb
regulatory pathway from the U.S. Food and Drug Administration in Q4 2021
LOS ALTOS, Calif., November
11, 2021 -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients
with kidney disease, today reported financial results for the third quarter ended September
Shalabh Gupta, M.D., Chief Executive Officer,
stated, "With our addition to the Russell Microcap Index and conference participation, we made meaningful corporate progress to expand
the interest and visibility of Unicycive within the investment community last quarter. We are also pleased to have biopharmaceutical executive
Douglas Jermasek on our team whose broad experience working with kidney disease treatments has already made a huge impact."
"In chronic kidney disease (CKD), hyperphosphatemia
is caused by a chronic dysregulation of phosphates and occurs in at least 70% of patients with Stage 5 CKD. Current treatments for hyperphosphatemia
come with a very high pill burden that can result in poor patient adherence. Our lead program, Renazorb, combines one of the most potent
phosphate lowering agents with a smaller, easier swallowed pill to potentially improve the treatment outcomes for patients. We are working
with the U.S. Food and Drug Administration (FDA) on our regulatory pathway for Renazorb and expect to receive confirmatory guidance in
Q4 2021," added Dr. Gupta.
Key Highlights and Upcoming Milestones
Third Quarter 2021 Financial Results
Research and development expenses for the third
quarter of 2021 were $3.8 million, compared to $0.3 million for the third quarter of 2020. This increase was primarily attributable to
a one-time $2.2 million increase in non-cash expense from the issuance of common stock pursuant to the anti-dilution clause in the purchase
of in process research and development technology to the Renazorb licensor. This represents the final anti-dilution share issuance to
General and administrative expenses for the third
quarter of 2021 were $0.9 million, compared to $0.3 million for the third quarter of 2020. This increase was primarily attributable to
an increase of $0.3 million in insurance expense for directors and officers.
Net loss for the third quarter of 2021 was $5.2
million, or $0.37 per share of common stock, compared to a net loss of $0.7 million, or $0.08 per share of common stock, for the third
quarter of 2020. This increase was primarily attributable to non-cash stock issuance expense in the current period.
As of September 30, 2021, cash and cash equivalents
totaled $18 million.
Unicycive is a biotechnology company developing
novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the
treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of
acute kidney injury. For more information, please visit www.unicycive.com.
Forward-looking statement
statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated"
and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These
forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are a
number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors
include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier
studies and trials may not be predictive of future trial results; our pre-clinical studies may be suspended or discontinued due to unexpected
side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including
the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; uncertainties
of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial
competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain
FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technology or product candidates
will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed
or successful or that any therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors
should read the risk factors set forth in our Form 10-Q for the quarter ended September 30, 2021 and in our registration statement on
Form S-1 and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered
representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors
may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein
are made as of the date hereof, and Unicycive does not undertake any obligation to update publicly such statements to reflect subsequent
events or circumstances.
Unicycive Therapeutics, Inc.
(in thousands, except for share and per share
| As of | As of | |||||||
| December 31, | September 30, | |||||||
| 2020 | 2021 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | - | $ | 18,011 | ||||
| Prepaid related party service fee | - | 58 | ||||||
| Deferred offering costs | 200 | - | ||||||
| Prepaid expenses and other current assets | 4 | 1,713 | ||||||
| Total current assets | 204 | 19,782 | ||||||
| Total assets | $ | 204 | $ | 19,782 | ||||
| Liabilities and stockholders' (deficit) equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 184 | $ | 49 | ||||
| Related party service fee payable | 9 | - | ||||||
| Accrued liabilities | 168 | 633 | ||||||
| Convertible notes | 1,528 | - | ||||||
| Loan from stockholder | 967 | 103 | ||||||
| Government loan | 19 | - | ||||||
| Total current liabilities | 2,875 | 785 | ||||||
| Total liabilities | 2,875 | 785 | ||||||
| Commitments and contingencies (Note 7) | ||||||||
| Stockholders' (deficit) equity: | ||||||||
| Preferred stock: $0.001 par value per share-10,000,000 shares authorized at December 31, 2020 and September 30, 2021 (unaudited); no shares issued and outstanding at December 31, 2020 and September 30, 2021 (unaudited) | $ | - | $ | - | ||||
| Common stock, $0.001 par value per share - 200,000,000 shares authorized at December 31, 2020 and September 30, 2021 (unaudited); 8,514,070 shares issued and outstanding at December 31, 2020, and 14,972,552 shares issued and outstanding at September 30, 2021 (unaudited) | 9 | 15 | ||||||
| Additional paid-in capital | 3,242 | 32,169 | ||||||
| Accumulated deficit | (5,922 | ) | (13,187 | ) | ||||
| Total stockholders'(deficit) equity | (2,671 | ) | (18,997 | ) | ||||
| Total liabilities and stockholders' (deficit) equity | $ | 204 | $ | 19,782 |
Unicycive Therapeutics, Inc.
Statements of Operations
(in thousands, except for share and per share
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2020 | 2021 | 2020 | 2021 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 304 | $ | 3,776 | $ | 633 | $ | 4,719 | ||||||||
| General and administrative | 322 | 939 | 670 | 1,506 | ||||||||||||
| Total operating expenses | 626 | 4,715 | 1,303 | 6,225 | ||||||||||||
| Loss from operations | (626 | ) | (4,715 | ) | (1,303 | ) | (6,225 | ) | ||||||||
| Other expenses: | ||||||||||||||||
| Interest expense | (76 | ) | (55 | ) | (81 | ) | (628 | ) | ||||||||
| Loss on debt conversion | - | (431 | ) | - | (431 | ) | ||||||||||
| Gain on extinguishment of debt | - | - | - | 19 | ||||||||||||
| Total other expenses | (76 | ) | (486 | ) | (81 | ) | (1,040 | ) | ||||||||
| Net loss | $ | (702 | ) | $ | (5,201 | ) | $ | (1,384 | ) | $ | (7,265 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.08 | ) | $ | (0.37 | ) | $ | (0.16 | ) | $ | (0.69 | ) | ||||
| Weighted-average shares outstanding used in computing net loss per share, basic and diluted | 8,514,070 | 14,167,098 | 8,494,858 | 10,538,473 |
SOURCE: Unicycive Therapeutics, Inc.